Astellas Pharma Inc (Astellas) has acquired Universal Cells Inc for $102.5m.
The acquirer company is a pharmaceutical company based in the US, while the acquired company, also based in the US, is a biotech company.
Go deeper with GlobalData
The acquisition will enable Astellas Pharma to use Universal Cells’ proprietary Universal Donor Cell technology to manufacture cell therapy products in a number of therapeutic areas.
Shenzhen Neptunus Bioengineering has agreed to acquire a 60% share in a medical tech company based in Tianjin for CNY48.6m ($7.69m).
The Chinese pharmaceutical company will complete the transaction through its Ningbo-based trade unit.
Mallinckrodt Pharmaceuticals has completed the acquisition of Sucampo Pharmaceuticals for $1.2bn.
The acquisition was announced in December 2017 and will add Sucampo’s AMITIZA (lubiprostone), RESCULA, VTS-270 and CPP-1X / sulindac products to Mallinckrodt’s portfolio.
Deutsche Bank was appointed as the financial advisor for the transaction by Mallinckrodt, and Wachtell, Lipton, Rosen & Katz as the legal advisor.
Jefferies served as the exclusive financial advisor for Sucampo and Cooley served as the legal advisor for the transaction.
